Atara Biotherapeutics (ATRA)
(Delayed Data from NSDQ)
$8.27 USD
+0.10 (1.22%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $8.46 +0.19 (2.30%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Brokerage Reports
Atara Biotherapeutics, Inc. [ATRA]
Reports for Purchase
Showing records 41 - 60 ( 110 total )
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2022 Expected Milestones; Positive Tab-Cel Data at ASH 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Interim Phase III (ALLELE) Safety and Efficacy Data Shared at ASH
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Catalysts from Our Coverage Universe: YE2021 and Beyond
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q21: tab-cel BLA Filing to Complete in 2Q22 Now
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
New ATA188 Progressive Multiple Sclerosis Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
An Imaging Technique May Elucidate Benefit in Multiple Sclerosis
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tab-Cel Commercialization Agreement Inked With Pierre Fabre; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
tab-cel ex-U.S. Commercialization Agreement Signed with Pierre Fabre
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tab-Cel Granted Accelerated Assessment by the EMA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Tab-Cel Rolling BLA Completion Slated for 1Q22; 2Q21 Financials; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q21: tab-cel BLA Filing Timeline Delayed. PT reduced to $28.
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Atara Biotherapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q21: The Next 12-18 Months Are Most Important
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T